You missed the vital bit @madamswer. The announcement you quote specified that the inventory buildup was specifically for paediatric SR aGvHD. (also some use in other areas). No mention of Covid-ARDS. Of course.
Rem-L for Covid-ARDS was not even on the radar at that time. Not outside MSB, anyway.
I share the general excitement here that the $100M will mostly be applied to inventory of Rem-L for ARDS. Possibly for label extensions also. All the signs point to high confidence of management for a very near, very large market for Rem-L.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.35 |
Change
0.050(2.17%) |
Mkt cap ! $3.007B | |||
| Open | High | Low | Value | Volume |
| $2.29 | $2.39 | $2.27 | $9.283M | 3.962M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 275 | $2.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.38 | 5902 | 1 |
View Market Depth
| Last trade - 16.14pm 18/09/2025 (20 minute delay) ? |
| MSB (ASX) Chart |